Skip to content

Metabolomics studies in patients with acute heart failure

Metabolomics studies in patients with acute heart failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17011168
Enrollment
Unknown
Registered
2017-04-18
Start date
2017-05-01
Completion date
Unknown
Last updated
2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

illness group:No
control group:No

Sponsors

QiLu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria of healthy controlsd: 1. Aged at least 18 years; 2, BMI in 18 to 31; 3. At least 2 weeks before blood taking without using hormonal contraception, topical estrogen preparations, statin drugs, diabetes drugs, anti-inflammatory drugs, no drug allergy conditions; 4. Without using anticoagulants; 5. Without heart disease, high blood pressure, diabetes, liver disease, kidney disease, tumors, cachexia, major operations, inflammation, autoimmune disease and genetic metabolic diseases; Inclusion criteria of illness group: 1. Aged at least 18 years; 2. Acute coronary syndrome patients who is accordant to the diagnostic criteria of acute heart failure in 2014 edition of the Chinese medical association "guidelines of heart failure's diagnosis and treatment in China".

Exclusion criteria

Exclusion criteria: Exclusion criteria of healthy controls: 1. The existence of risk factors of cardiovascular event (overweight, high low density lipoprotein cholesterol (ldl-c) and high triglycerides, high blood pressure, diabetes, smoking); 2. Pregnancy. Exclusion criteria of illness group: 1. Using hormonal contraception, topical estrogen, lipid drugs, diabetes drugs, anti-inflammatory drugs, or drug allergy within 2 weeks before blood taking; 2. Having diabetes, liver disease, kidney disease, tumor, cachexia, major operations, inflammation,autoimmune disease, and genetic metabolic diseases. 3. Pregnancy.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;

Countries

China

Contacts

Public ContactMengxiong Tang

QiLu Hospital of Shandong University

mengxiongtang@aliyun.com+86 18560083056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026